08:00 , Nov 11, 2013 |  BC Week In Review  |  Company News

Adial, Cato BioVentures deal

ADial and VC firm Cato entered a deal under which the VC will invest $1.8 million in ADial in exchange for Cato's affiliate Cato Research Ltd. serving as ADial's preferred CRO for clinical trials of...
08:00 , Feb 13, 2012 |  BC Week In Review  |  Company News

Cato Research Ltd., VistaGen deal

VistaGen partnered with CRO Cato Research and its Cato Ventures venture capital affiliate to indentify and develop small molecule drugs candidates that were discontinued in preclinical development by pharmaceuticals companies due to heart or liver...
07:00 , Aug 10, 2009 |  BC Week In Review  |  Financial News

Senesco proposes private placement of common stock and warrants

Senesco Technologies Inc. (NYSE-A:SNT), New Brunswick, N.J.   Business: Cancer, Autoimmune, Agbio/Environmental   Date announced: 7/30/09   Type: Private placement of common stock and warrants   To be raised: Up to $704,999   Shares: 783,332...
07:00 , Apr 28, 2008 |  BC Week In Review  |  Company News

Echo Therapeutics, Cato Research Ltd. deal

Cato granted Echo an exclusive right of first negotiation to all dermatology products and transdermal drug delivery technology identified or acquired by Cato through December 2009. Cato owns 21% of Echo. Financial terms were not...
07:00 , Apr 7, 2008 |  BC Week In Review  |  Company News

Advanced Targeting Systems Inc., Cato Research neurology news

Cato and Advanced Targeting formed a JV called Advanced Pain Therapeutics LLC to develop and commercialize Advanced Targeting's Substance P- Saporin (SP-SAP) to treat chronic pain. The chemical conjugate of neurokinin 1 (NK1, substance P)...
07:00 , Jun 25, 2007 |  BioCentury  |  Finance

Ebb & Flow

Stocks generally fall to account for dilution when companies propose follow-ons. But shares of Transgene (Euro-next:Transgene) rose both before and after the company's offering last week. Generalist investors from across the continent with little exposure...
07:00 , Apr 3, 2006 |  BC Week In Review  |  Company News

AtheroGenics management update

AtheroGenics Inc. (AGIX), Atlanta, Ga.   Business: Cardiovascular, Autoimmune, Transplant   Hired: Walker Long as VP of clinical research, formerly SVP of worldwide project operations at Cato Research  ...
08:00 , Mar 27, 2006 |  BC Week In Review  |  Company News

VistaGen, Cato Research Ltd. deal

VistaGen received exclusive rights of first negotiation for all CNS products acquired or identified by Cato. Further terms were not disclosed. VistaGen Therapeutics Inc. , Burlingame, Calif.   Cato Research Ltd. , Durham, N.C.  ...
08:00 , Jan 17, 2005 |  BioCentury  |  Regulation

Electronic NDA filings

Electronic NDA filings Company Product Indication Electronic filing (Outside consultant) NDA accepted Status Adolor/ GlaxoSmithKline Entereg Post-operative ileus (POI) Full (Liquent) 9/8/04 PDUFA date (4/25/05) Avanir Neurodex Emotional lability Full (Cato Research) NA Complete rolling...
08:00 , Nov 24, 2003 |  BC Week In Review  |  Company News

Artemis Neuroscience Inc., VistaGen deal

VistaGen acquired Artemis, which develops therapeutics for epilepsy, neuropathic pain and other CNS disorders. Through the acquisition, VistaGen added to its pipeline Artemis' AV-101 , a preclinical compound for epilepsy. VistaGen believes the indirectly acting...